Eyepoint Pharmaceuticals’ partner Ocumension won approval for its eye implant in China. The decision by the National Medical Products Administration (NMPA) was based entirely on real-world data (RWD), a first in the country. The product, Yutiq, is a sustained-released implant that lasts up to 36 months.
According to , “Ocumension laid the groundwork for approval by teaming up with Boao Lecheng Super Hospital in September. Together, the hospital and Ocumension studied Yutiq in the treatment of chronic, non-infectious uveitis affecting the posterior segment of the eye. Ocumension said its research showed the fluocinolone implant Yutiq can significantly cut the recurrence rate and disease burden for patients with chronic noninfectious uveitis and improve visual acuity.”
To read more, click here.
(Source: Fierce Pharma, June 21st, 2022)
